HER2/neu-positive breast cancer, a more aggressive subtype associated with poorer survival outcomes [14], requires a monoclonal antibody-based therapy such as Trastuzumab to target the overexpressed protein kinase [21]. This evidence concerns the gene ERBB2 and breast cancer.